Celgene Corporation (CELG) : Mcrae Capital Management Inc scooped up 2,525 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 119,630 shares of Celgene Corporation which is valued at $13,893,828.Celgene Corporation makes up approximately 6.17% of Mcrae Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Matterhorn Capital Management reduced its stake in CELG by selling 7,038 shares or 34.56% in the most recent quarter. The Hedge Fund company now holds 13,329 shares of CELG which is valued at $1,548,030. Celgene Corporation makes up approx 0.96% of Matterhorn Capital Management’s portfolio.Pacific Heights Asset Management reduced its stake in CELG by selling 2,000 shares or 1.82% in the most recent quarter. The Hedge Fund company now holds 108,000 shares of CELG which is valued at $11,675,880. Celgene Corporation makes up approx 1.03% of Pacific Heights Asset Management’s portfolio.Sumitomo Life Insurance Co reduced its stake in CELG by selling 1,540 shares or 3.4% in the most recent quarter. The Hedge Fund company now holds 43,720 shares of CELG which is valued at $4,490,044. Celgene Corporation makes up approx 0.60% of Sumitomo Life Insurance Co’s portfolio.Davis R M Inc boosted its stake in CELG in the latest quarter, The investment management firm added 1,090 additional shares and now holds a total of 4,450 shares of Celgene Corporation which is valued at $457,015. Celgene Corporation makes up approx 0.02% of Davis R M Inc’s portfolio.
Celgene Corporation closed down -1.9 points or -1.64% at $113.63 with 58,53,745 shares getting traded on Monday. Post opening the session at $115.49, the shares hit an intraday low of $112.75 and an intraday high of $115.53 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.